ARPO Aerpio Pharmaceuticals Inc

Centurion Law Group Acquires IMANI- Lawyers On Demand and launches an Africa-wide Flexible Legal Services Model

Centurion Law Group / Key word(s): Takeover
Centurion Law Group Acquires IMANI- Lawyers On Demand and launches an Africa-wide Flexible Legal Services Model

05-Nov-2018 / 10:25 CET/CEST


Centurion Law Group Acquires IMANI- Lawyers On Demand and launches an Africa-wide Flexible Legal Services Model

JOHANNESBURG, South Africa - Nov. 5, 2018 - Centurion Law Group (Centurion) (), a pan-African law conglomerate, now offers the cost savings and efficiency of flexible legal services through its acquisition of IMANI-African Lawyers On Demand. .

Through Centurion Plus, a division of Centurion, corporate clients throughout Africa can select from a pool of approximately 190 carefully vetted, on-demand attorneys for temporary and project-based legal services.

"Flexible legal services have transformed the legal industry in the United States, Canada, Europe and regions of Asia," says NJ Ayuk, CEO of Centurion Law Group. "We're confident that with our massive capital investment in technology and human resources, it will be equally successful in Africa. We are very bullish about this.

"This model provides African businesses, state companies and corporate legal departments with an affordable means of accessing top attorneys from around the Africa including the diaspora," Ayuk adds. "Flexible legal services also makes sense for foreign investors looking to do business in Africa. Centurion Plus connects them with attorneys who can help them navigate all of the tax, regulatory, litigation, and local content requirements they'll encounter here while keeping their expenses under control."

Centurion has always differentiated itself by our ability to get the deal done and being pan African and Pro African. Our growth strategy works well thanks to a strong collaboration with international law firms from the United States of America, the United Kingdom and Europe. The Africa market has changed so much that we now offer work to our western counterparts where skills are lacking in Africa.

Centurion Plus attorneys have full access to Centurion's extensive suite of resources and connections. With the firm's significant leverage and reach, clients who choose on-demand services in lieu of more traditional full-time legal representation are assured of the same level of expertise that has come to signify Centurion Law Group.

 

About Centurion:

Centurion () is a leading pan-African legal and business advisory group with extensive experience in oil and gas law. The group provides outsourced legal representation and covers a full suite of practice areas for its clients, including arbitration and commercial litigation, corporate law, tax and anti-corruption advisory and contract negotiation. Centurion specialises in assisting clients that are starting or growing a business in Africa with offices and Affiliates in Ghana, Cameroon, Congo, Equatorial Guinea, South Africa, South Sudan, Nigeria, Gabon, Angola and Senegal.

Visit Centurion's website:



Dissemination of a Financial Wire News, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.


741013  05-Nov-2018 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=741013&application_name=news&site_id=research_pool
EN
05/11/2018

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Aerpio Pharmaceuticals Inc

 PRESS RELEASE

Aadi Bioscience to Join Russell 2000® and Russell 3000® Indexes

Aadi Bioscience to Join Russell 2000® and Russell 3000® Indexes LOS ANGELES, June 23, 2022 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes, today announced it will join both the U.S. small cap Russell 2000® Index and broad-market Russell 3000® Index at the conclusion of the 2022 Russell indexes annual reconstitution, effective immediately after the U.S. market opens on June 24, 2022 according to a preliminary list of add...

 PRESS RELEASE

Aadi Bioscience to Present at the Jefferies Global Healthcare Conferen...

Aadi Bioscience to Present at the Jefferies Global Healthcare Conference LOS ANGELES, June 01, 2022 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes, today announced members of the Aadi senior management team will participate in the Jefferies Global Healthcare Conference, to be held in New York, NY June 8-10, 2022. Founder, Chief Executive Officer and President, Neil Desai, Ph.D. is scheduled to present live during a fire...

 PRESS RELEASE

Aadi Bioscience Appoints Marcy Graham Senior Vice President Investor R...

Aadi Bioscience Appoints Marcy Graham Senior Vice President Investor Relations and Corporate Communications LOS ANGELES, May 31, 2022 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes, today announced the appointment of Marcy Graham to the new position of Senior Vice President, Investor Relations (IR) and Corporate Communications. “We are delighted to welcome Marcy to the team, as she brings extensive experience to ...

 PRESS RELEASE

Aadi Bioscience Announces Exploratory Biomarker Data from Patients in ...

Aadi Bioscience Announces Exploratory Biomarker Data from Patients in Its AMPECT Trial and Expanded Access Program to be Presented at 2022 ASCO Annual Meeting Target tumor reductions observed in advanced malignant PEComa patients harboring TSC1 or TSC2 inactivating alterations regardless of prior mTOR inhibitor exposure LOS ANGELES, May 26, 2022 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes, today announced presentat...

 PRESS RELEASE

Aadi Bioscience to Present at the H.C. Wainwright Global Investment Co...

Aadi Bioscience to Present at the H.C. Wainwright Global Investment Conference LOS ANGELES, May 18, 2022 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (Nasdaq: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced that Founder, Chief Executive Officer and President, Neil Desai, Ph.D., and senior members of Aadi’s executive team will participate virtually in the H.C. Wainwright Global Investment Conference, to be held in person and virtually May 23-26, 2022 in Mia...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch